Three senators are demanding that drugmaker Pfizer Inc. produce documents about its deals with insurers to get them to cover its cholesterol blockbuster Lipitor, rather than two generic versions just hitting drugstores.
Lipitor got U.S. generic competition on Wednesday. Pfizer has offered insurance plans big discounts if they require pharmacies to dispense brand-name Lipitor rather than generic copies for the next six months. After that, more generic versions will arrive and prices will plunge.
The strategy has generated controversy and a couple of media reports claiming the deals would raise costs for health plan sponsors — employers and taxpayers. Pfizer denies that, but the senators have given the company three weeks to provide extensive documents on the deals.